mRNA Cancer Vaccine Shows Promise, Could Boost Vaccination Attitudes

The clinical success of an mRNA vaccine against melanoma, developed by Moderna and Merck, has given specialists reason to be hopeful about the future of this technology. The vaccine's development was supported by Operation Warp Speed, which helped finance and accelerate its creation.

mRNA technology enables scientists to direct cells to produce virtually any protein or fragments of it by changing the genetic code of the mRNA. This property made it possible to develop Covid-19 vaccines in less than a year.

Mass General Brigham physician and immunologist Ryan Sullivan, who worked with Moderna, believes that the success of cancer vaccination could affect attitudes toward vaccination in society.

Sullivan suggests that this may lead people to perceive the words 'vaccine' and 'mRNA' less negatively, although he acknowledges that it is unlikely to completely eliminate the stigma surrounding vaccines.